München

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• HIV5 trials
• Colorectal cancer2 trials
• Asthma1 trial
• Chronic rhinosinusitis with nasal polyps1 trial
• Lung cancer1 trial
• Pancreatic cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 37 trials
• Phase 1/21 trial
• Phase 21 trial

Status

• Active, not recruiting6 trials
• Completed2 trials
• Recruiting2 trials

Lead sponsor

• GlaxoSmithKline5 trials
• ViiV Healthcare5 trials

Running trials

• Recruiting

  A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  NCT07099898· Phase 3· GlaxoSmithKline· Source

  Contact: Diego Kauffmann-Guerrero (principal investigator)

• Recruiting

  A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

  NCT06885034· Phase 1/2· GlaxoSmithKline· Source

  Contact: Stefan Boeck (principal investigator)

• Active, not recruiting

  A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

  NCT05723562· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

  NCT04915755· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

  NCT03299049· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

  NCT02951052· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

  NCT02938520· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

  NCT02362503· Phase 3· ViiV Healthcare· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Lung cancer1 recruiting
• Pancreatic cancer1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

  NCT05274750· Phase 3· GlaxoSmithKline· Source

• Completed

  Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany

  NCT03754803· ViiV Healthcare· Source